Buscar
Inhibrx Biosciences Inc
INBXAñadir a la lista de seguimiento
82.050USD
-2.680-3.16%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.20BCap. mercado
PérdidaP/E TTM
Más Datos de Inhibrx Biosciences Inc Compañía
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
Información de Inhibrx Biosciences Inc
Símbolo de cotizaciónINBX
Nombre de la empresaInhibrx Biosciences Inc
Fecha de salida a bolsaMay 28, 2024
Director ejecutivoLappe (Mark P)
Número de empleados156
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 28
Dirección11025 N. Torrey Pines Road, Suite 140
CiudadLA JOLLA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92037
Teléfono18587954220
Sitio Webhttps://inhibrx.com/
Símbolo de cotizaciónINBX
Fecha de salida a bolsaMay 28, 2024
Director ejecutivoLappe (Mark P)
Ejecutivos de Inhibrx Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
1.06M
--
Ms. Kimberly J. Manhard
Ms. Kimberly J. Manhard
Independent Director
Independent Director
10.00K
--
Mr. Mark P. Lappe
Mr. Mark P. Lappe
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Kelly D. Deck, CPA
Ms. Kelly D. Deck, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas G. Forsyth
Mr. Douglas G. Forsyth
Independent Director
Independent Director
--
--
Dr. Kristiina S. Vuori, M.D., Ph.D.
Dr. Kristiina S. Vuori, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. David J. Matly
Mr. David J. Matly
President, Chief Commercial and Business Development Officer
President, Chief Commercial and Business Development Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
1.06M
--
Ms. Kimberly J. Manhard
Ms. Kimberly J. Manhard
Independent Director
Independent Director
10.00K
--
Mr. Mark P. Lappe
Mr. Mark P. Lappe
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Kelly D. Deck, CPA
Ms. Kelly D. Deck, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas G. Forsyth
Mr. Douglas G. Forsyth
Independent Director
Independent Director
--
--
Dr. Kristiina S. Vuori, M.D., Ph.D.
Dr. Kristiina S. Vuori, M.D., Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Inhibrx Biosciences Inc?
Los cinco principales accionistas de Inhibrx Biosciences Inc son: Dr. Jon Faiz Kayyem, Ph.D.
¿Cuántas instituciones poseen acciones de Inhibrx Biosciences Inc (INBX)?
A fecha de 2026Q1, 258 instituciones poseen acciones de Inhibrx Biosciences Inc, con un valor de mercado combinado de aproximadamente 12.34M, lo que representa el 84.51% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 990598.00.